Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, Arenillas L, Valcarcel D, Vallespí T, Costa D, Nomdedeu B, Jimenez MJ, Granada I, Grau J, Ardanaz MT, de la Serna J, Carbonell F, Cervera J, Sierra A, Luño E, Cervero CJ, Falantes J, Calasanz MJ, González-Porrás JR, Bailén A, Amigo ML, Sanz G, Solé F. Sánchez-Castro J, et al. Leuk Res. 2013 Jul;37(7):769-76. doi: 10.1016/j.leukres.2013.04.010. Epub 2013 Apr 29. Leuk Res. 2013. PMID: 23639672 Free article.
Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Luño E, Ardanaz M, Ramos F, Pedro C, Gomez V, de Paz R, Sanchez-Barba M, Sanz GF, Del Cañizo AC; Spanish Myelodysplastic Syndrome Registry. Gonzalez-Porras JR, et al. Cancer. 2011 Dec 15;117(24):5529-37. doi: 10.1002/cncr.26173. Epub 2011 Jun 2. Cancer. 2011. PMID: 21638279 Free article.
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.
Cordoba I, Gonzalez-Porras JR, Such E, Nomdedeu B, Luño E, de Paz R, Carbonell F, Vallespi T, Ardanaz M, Ramos F, Marco V, Bonanad S, Sanchez-Barba M, Costa D, Bernal T, Sanz GF, Cañizo MC. Cordoba I, et al. Leuk Res. 2012 Mar;36(3):287-92. doi: 10.1016/j.leukres.2011.10.025. Epub 2011 Nov 30. Leuk Res. 2012. PMID: 22133642
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Falantes J, et al. Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30. Leuk Res. 2015. PMID: 25487012 Clinical Trial.
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, Revilla N, González-Porras JR, Bolaños E, Rodríguez-López MA, Orna-Montero E, Vicente V. Lozano ML, et al. Sci Rep. 2019 Nov 13;9(1):16680. doi: 10.1038/s41598-019-53209-y. Sci Rep. 2019. PMID: 31723222 Free PMC article.
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.
Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, González-Porras JR, Bolaños E, López-Ansoar E, Orna-Montero E, Vicente V. Lozano ML, et al. Blood Cells Mol Dis. 2021 Feb;86:102505. doi: 10.1016/j.bcmd.2020.102505. Epub 2020 Sep 20. Blood Cells Mol Dis. 2021. PMID: 32979651 Free article.
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
García-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, López R, Grande-García C, Alegre A, Vargas-Pabón M, Gutiérrez ON, Rodríguez JA, San Miguel JF. García-Sanz R, et al. Leukemia. 2004 Apr;18(4):856-63. doi: 10.1038/sj.leu.2403322. Leukemia. 2004. PMID: 14973508 Clinical Trial.
130 results